Skip to content
Governance Register
Sign inFind yourself
Find yourselfSign in
Search How it works For organisations For professionals

Edition

United Kingdom (current)IrelandUnited StatesNew ZealandCanadaAustraliaScotlandNorthern Ireland

Company · Bristol

Ducentis Biotherapeutics LTD.

Research and experimental development on biotechnology

How am I connected?
More
View network map Report an issue

Official record Companies House · updated 27th September 2026 · Sources

Network

The large node is Ducentis Biotherapeutics LTD.. Red nodes are organisations, white nodes are people. Sign in free to explore further.

Who leads it

Previous officers 13

  1. David Joseph Topper 2024-2025 Director View profile
  2. Jessica Lynn Robison 2023-2024 Director View profile
  3. Scott Loren Burrows 2022-2023 Director View profile
  4. Matthew Moore 2022-2024 Director View profile
  5. Dr Alan Paul Watt 2021-2022 Director View profile
  6. Clare Elizabeth Terlouw 2021-2022 Director View profile
  7. Dr David Mark Anthony Holbrook 2019-2021 Director View profile
  8. Philippe Lenoble 2019-2022 Director View profile
  9. Andrea Giacomo Mica 2019-2022 Director View profile
  10. Professor David John Blackbourn 2015-2022 Director View profile
  11. Dr Rebecca Ashfield 2015-2022 Director View profile
  12. Toby Morris 2014-2015 Secretary View profile
  13. Dr Philip Huxley 2014-2022 Secretary View profile

Directors and secretaries as filed at Companies House.

Do you help lead this organisation? Set up its network · How it works

About

What it does
Research and experimental development on biotechnology
Incorporated
12/11/2014
Registered office
Bristol
Previous names
Tripos Biopharma LTD. (until 06/07/2015)
Ducentis Biotherapeutics LTD. (until 08/05/2015)
Deucentis Limited (until 17/11/2014)

Ownership

Owned by (1) iOwned byIndividuals and companies registered as having significant control over this company, from the Companies House PSC (persons with significant control) register. People whose ownership could not be confirmed to one individual are not listed as confirmed owners.

  • Lifearc ceased 2022-09-09
    25-50% shares · notified 2019-08-06

Group

  1. Ducentis Biotherapeutics LTD. is controlled by Lifearc
    Evidence
    ceased 25-50% shares · notified 2019-08-06, ceased 2022-09-09 · source: Companies House PSC register

Ultimately controlled by Lifearc.

4 other companies in this group

Ownership paths are calculated from Companies House persons-with-significant-control filings. Each step shows the filed nature of control and dates; a step marked "ceased" is historical, not current.

Financials

Employees
0.03
Turnover
Not reported (small or micro-entity accounts)
Profit/loss
-£7,839,323

Figures from accounts filed at Companies House (iXBRL), period ending 2025-12-31. Where turnover is absent, small and micro-entity accounts are not required to report it, so it is not shown as zero.

Board analysis

Board DNA

How this board is put together, from the Companies House officer record and Charity Commission trustee records - deterministic, no AI.iBoard compositionCounted from the dated Companies House officer record: the current directors only, past directors excluded.

3 directors on the board

2.5y median 2.6y
average tenure
3.8y
longest tenure
0
directors past 6 years

First-time vs portfolio directors

First-time (3)

0
also govern a charity
0
left in the last 12 months

Sources

Official record from Companies House. Governance Register calculates the connections.

Record details
Company number
09307415
Status
Active
Type
Private Limited Company
Accounts next due
30/09/2027
Edition
Register edition compiled 27th September 2026
Labels
Official record from Companies House · Calculated derived by Governance Register.

Contains public sector information licensed under the Open Government Licence v3.0. Report an issue · How we handle data